GHRH antagonists reduced prostate size in experimental benign prostatic hyperplasia, with effects comparable to finasteride — offering a novel GH-axis-based approach to treating enlarged prostate without affecting testosterone.
Key findingGHRH antagonists reduced prostate size in experimental benign prostatic hyperplasia, with effects comparable to finasteride — offering a novel GH-axis
What the researchers found
GHRH antagonists reduced prostate size in experimental benign prostatic hyperplasia, with effects comparable to finasteride — offering a novel GH-axis-based approach to treating enlarged prostate without affecting testosterone.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Proceedings of the National Academy of Sciences of the United States of America, 108(9), 3755-60
Citation
Rick, Ferenc G; Schally, Andrew V; Block, Norman L; Nadji, Mehrdad; Szepeshazi, Karoly; Zarandi, Marta; Vidaurre, Irving; Perez, Roberto; Halmos, Gabor; Szalontay, Luca. (2011). Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.. Proceedings of the National Academy of Sciences of the United States of America, 108(9), 3755-60. https://doi.org/10.1073/pnas.1018086108